As the development of new drugs for Chagas disease is not a priority due to its neglected disease status, an option for increasing treatment adherence is to explore alternative treatment regimens, which may decrease the incidence of side effects. Therefore, we evaluated the efficacy of different therapeutic schemes with benznidazole (BNZ) on the acute and chronic phases of the disease, using mice infected with strains that have different BNZ susceptibilities. Our results show that the groups of animals infected by VL-10 strain, when treated in the chronic phase with a lower dose of BNZ for a longer period of time (40 mg/kg/day for 40 days) presented better treatment efficacy than with the standard protocol (100 mg/kg/day for 20 days) although the best result in the treatment of the animals infected by the VL-10 strain was with100 mg/kg/day for 40 days. In the acute infection by the Y and VL-10 strains of T. cruzi, the treatment with a standard dose, but with a longer time of treatment (100 mg/kg/day for 40 days) presented the best results. Given these data, our results indicate that for BNZ, the theory of dose and time proportionality does not apply to the phases of infection.
Trypanosoma cruzi; Benznidazole; Therapeutic strategies
Fonseca KDS, Perin L, de Paiva NCN, da Silva BC, Duarte THC, Marques FS, et al. Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain. Pathogens. 2021 Jun 9;10(6):729.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/7046
This item appears in following collections
- HVH - Articles científics 
The following license files are associated with this item: